



# Baseline characteristics of SELECT trial participants

N=17,605

## Male or female



## HbA<sub>1c</sub> (%), mean



5.78%

SD 0.34

Prediabetes: 64%

## Race: n (%)



Asian	1,447 (8.2)
Black	671 (3.8)
White	14,791 (84.0)
Other	527 (3.0)

# Baseline characteristics of SELECT trial participants


N=17,605



**Age**  
**61.6** years  
 SD 8.9

## Age group (years), n (%)


45 to <55:	4,150 (23.6)
55 to <65:	6,727 (38.2)
65 to <75:	5,362 (30.5)
75 to <85:	1,318 (7.5)
≥85:	40 (0.3)



**BMI**  
**33.34** kg/m<sup>2</sup>  
 SD 5.0

## BMI category (kg/m<sup>2</sup>): n (%)

<30:	5,024 (28.5)
30 to <35:	7,475 (42.5)
35 to <40:	3,346 (19.0)
40 to <45:	1,174 (6.7)
≥45:	586 (3.3)



**eGFR**  
**82.5** mL/min/1.73 m<sup>2</sup>  
 SD 17.4


## Renal function, eGFR (mL/min/1.73 m<sup>2</sup>): n (%)

Normal, ≥90:	6,990 (39.7)
Mild RI, 60–<90:	8,557 (48.7)
Moderate RI, 30–<60:	1,826 (10.4)
Severe RI, 15–<30:	69 (0.4)

BMI, body mass index; eGFR, estimated glomerular filtration rate; RI, renal impairment; SD, standard deviation; SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity. Lingway I et al. Obesity (Silver Spring) 2023;31:111–22.

# Baseline characteristics of SELECT trial participants

N=17,605



CV, cardiovascular; MI, myocardial infarction; SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity. Lingway I et al. Obesity (Silver Spring) 2023;31:111–22.

# Baseline characteristics of SELECT trial participants

N=17,605

**High-sensitivity C-reactive protein, (mg/L), median (IQR)**

---

1.83 (0.87–4.12)

---

**Pulse (beats/min), mean (SD)**

---

68.8 (10.7)


---

**Lipids, (mg/dL), median (IQR)**

Total Cholesterol:	153.5 (131.1–182.9)
LDL-C:	78.1 (60.7–102.1)
HDL-C:	43.7 (37.1–51.8)
Triglycerides:	134.6 (98.3–187.8)

**Blood Pressure, (mmHg), mean (SD)**

Systolic BP:	131.0 (15.4)
Diastolic BP:	79.3 (10.0)



*IQR, interquartile range; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; BP, blood pressure. SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity. Lingvay I et al. Obesity (Silver Spring) 2023;31:111–22.*

# Baseline characteristics of SELECT trial participants

N=17,605



**CHF, n (%)**  
**4,274**  
(24.3)

## Subclass, n (%)

HFpEF:	2,268 (12.9)
HFrEF:	1,341 (7.6)
Unknown:	662 (3.8)

## NYHA class, n (%)

NYHA class I:	1,368 (7.8)
NYHA class II:	2,534 (14.4)
NYHA class III:	362 (2.1)
Unknown:	10 (<0.1)

## Obesity-related comorbidities, n (%)

CKD:	1,947 (11.1)
Knee osteoarthritis:	2,849 (16.2)
Hip osteoarthritis:	1,323 (7.5)
NAFL:	1,451 (8.2)
NASH:	115 (0.7)
Sleep apnoea:	2,542 (14.4)
Asthma:	1,187 (6.7)
COPD:	1,466 (8.3)
Gout:	1,532 (8.7)

CHF, chronic heart failure; CKD, chronic kidney disease; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NAFL, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NYHA, New York Heart Association; SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity. Lingvay I et al. Obesity (Silver Spring) 2023;31:111–22.

# Baseline characteristics of SELECT trial participants

## Concomitant CV-related medications

	Overall N=17,605
<b>Anti-hypertensive medications, n (%)</b>	<b>16,168 (91.8)</b>
Beta blockers	12,329 (70.0)
ACE inhibitors	7,915 (45.0)
Angiotensin receptor blockers	5,259 (29.9)
Calcium channel blockers	4,706 (26.7)
Angiotensin receptor-neprilysin inhibitor	254 (1.4)
<b>Lipid-lowering drugs, n (%)</b>	<b>15,804 (89.8)</b>
Statins	15,369 (87.3)
Ezetimibe	2,314 (13.1)
Fibrates	477 (2.7)
PCSK-9 inhibitors	335 (1.9)

	Overall N=17,605
<b>Diuretics, n (%)</b>	<b>5,861 (33.3)</b>
Loop diuretics	2,207 (12.5)
Thiazides	2,010 (11.4)
Aldosterone antagonists	1,808 (10.3)
Thiazide-like diuretics	1,014 (5.8)
<b>Platelet aggregation inhibitors, n (%)</b>	<b>15,130 (85.9)</b>
Acetylsalicylic acid	13,691 (77.8)
P2Y12 inhibitors	5,912 (33.6)
<b>Anticoagulant medications, n (%)</b>	<b>2,220 (12.6)</b>
DOAC	1,510 (8.6)
Vitamin K antagonists	670 (3.8)
<b>Anti-angina agents, n (%)</b>	<b>3,487 (19.8)</b>
<b>Anti-arrhythmic agents, n (%)</b>	<b>584 (3.3)</b>

CV, cardiovascular; PCSK-9, Proprotein convertase subtilisin/kexin type 9; DOAC, Direct oral anticoagulants.  
 SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity.  
 Lingvay I et al. *Obesity (Silver Spring)* 2023;31:111–22.